# OnCo record paper-talapro-2-lancet-2025-update (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-talapro-2-lancet-2025-update/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-talapro-2-lancet-2025-update" ;
  schema:name "Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial"@en ;
  schema:description "Later report from the TALAPRO-2 trial registered as NCT03395197, in The Lancet (2025); its title describes an updated or longer-term analysis."@en ;
  schema:url <https://onco.cc/key-papers/paper-talapro-2-lancet-2025-update/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s0140-6736(25)00684-1>, <https://pubmed.ncbi.nlm.nih.gov/40683290/>, <https://europepmc.org/article/MED/40683290>, <https://clinicaltrials.gov/study/NCT03395197> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s0140-6736(25)00684-1> ;
  schema:datePublished "2025"^^xsd:gYear ;
  schema:author "Agarwal N, Azad AA, Carles J, et al." ;
  onco:trials <https://onco.cc/trials/talapro-2/> ;
  onco:journals <https://onco.cc/journals/lancet/> .